ストックスクリーナーアプリを入手
2.60
4.26%
0.15
Jyong Biotech Ltd (MENS) 最新ニュース
MENS PE Ratio & Valuation, Is MENS Overvalued - Intellectia AI
Director of Jyong Biotech (MENS) files Form 3 showing 3,000 common shares - Stock Titan
Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3 - Stock Titan
Director at Jyong Biotech (MENS) discloses holding 3,000 shares - Stock Titan
Jyong Biotech (MENS) director Fan Hung-Shu files initial Form 3 - Stock Titan
Jyong Biotech (MENS) director files Form 3 with no insider trades - Stock Titan
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March - Defense World
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 - Bitget
A plant-based prostate drug finished Phase III trials in the U.S. and Taiwan - Stock Titan
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd PE Ratio (TTM) & PE Ratio (TTM) ChartsMENS - GuruFocus
Chinese firm sues Taiwan’s Jyong Biotech Ltd. in Cayman to enforce ¥152M China judgment - OffshoreAlert
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest - MarketBeat
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
MENS Earnings History & Surprises | EPS & Revenue Results | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
MENS Should I Buy - Intellectia AI
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%Time to Sell? - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia - The Manila Times
MENS Technical Analysis & Stock Price Forecast - Intellectia AI
Prostate cancer therapy also lowers cholesterol in 2-year trial - Stock Titan
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop - Yahoo Finance
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer By Investing.com - Investing.com India
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer - Investing.com Nigeria
Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer - TipRanks
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat
Jyong Biotech subsidiary announces phase II data for MCS-8 - TipRanks
Jyong Biotech reports positive results from MCS-8 phase II trial - Investing.com
Prostate cancer trial drug also improves cholesterol in 2-year study - stocktitan.net
Jyong Biotech Reports Higher Assets but Deeper Shareholders’ Deficit in June 2025 Unaudited Results - TipRanks
Jyong Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
FLYEXCLUSIVE INC. (FLYX) Stock, Price, News, Quotes, Forecast and Insights - MSN
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st
Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech Ltd.(NasdaqGM: MENS) added to NASDAQ Biotechnology Index - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry By Investing.com - Investing.com Nigeria
Jyong Biotech in Talks With Funds Interested in Buying Shares - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com
Jyong Biotech in talks with investment funds for purchasing co's ordinary shares - marketscreener.com
Jyong Biotech ‘not aware’ of any material information amid share price movement - TipRanks
Jyong Biotech Responds to Share Price and Volume Movement - The Manila Times
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
1.90%
1.08%
大文字化:
|
ボリューム (24 時間):